公开(公告)号：WO2017178587A1

公开(公告)日：2017-10-19

申请号：PCT/EP2017/058928

申请日：2017-04-13

申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  ENS - ECOLE NORMALE SUPÉRIEURE DE LYON ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) ,  UNIVERSITÉ CLAUDE BERNARD - LYON 1

发明人： GERLIER, Denis ,  BLANQUIER, Bariza ,  JEAN, Audrey ,  GROSJEAN, Isabelle

IPC分类号： C12Q1/68

CPC分类号： C12Q1/689 ,  C12Q2527/107 ,  C12Q2537/16 ,  C12Q2545/101

摘要： The present invention relates to a method for detecting mycoplasma 16S rDNA 1.5 kilobase fragment amplified by quantitative PCR. One of the most critical limitation of the qPCR is the DNA fragment length to amplify. The existing qPCR methods does not permit the amplification of long DNA fragments. Here the inventors demonstrate for the first time the amplification of mycoplasma 16S rDNA 1.5 kilobase fragment using qPCR based on real- time polymerase chain reaction. In particular, the present invention relates to a method for universal detection and quantification of mycoplasma 16S rDNA 1.5 kilobase fragment in a sample comprising contacting said sample with degenerate primers amplified by quantitative PCR or qPCR and using a DNA loading probe.

公开(公告)号：WO2016001276A1

公开(公告)日：2016-01-07

申请号：PCT/EP2015/064933

申请日：2015-07-01

申请人： INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM) ,  UNIVERSITÉ CLAUDE BERNARD LYON 1 ,  ECOLE NORMALE SUPÉRIEURE DE LYON ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)

发明人： GENESTIER, Laurent ,  BACHY, Emmanuel ,  DEFRANCE, Thierry

IPC分类号： G01N33/574

CPC分类号： C07K16/2833 ,  A61K31/713 ,  A61K38/13 ,  A61K39/39558 ,  A61K2039/505 ,  C07K16/3061 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/569 ,  C07K2317/76 ,  C12N15/115 ,  C12N2310/16 ,  C12N2320/31 ,  G01N33/57407 ,  G01N2333/70539

摘要： The present invention relates to methods for diagnosing and treating CD1d-restricted gamma/delta T cell lymphomas. In particular, the present invention relates to a method for diagnosing a T cell lymphoma as a CD1d-restricted gamma/delta T cell lymphoma in a patient in need thereof comprising i) detecting the presence of CD1d restricted gamma/delta T lymphoma cells in a cell lymphoma sample obtained from the patient and ii) concluding that the T cell lymphoma is a CD1d-restricted gamma/delta T cell lymphoma when the presence of CD Id restricted gamma/delta T cells is detected in the sample. The present invention also relates to a method for treating a CD1d-restricted gamma/delta T cell lymphoma as diagnosed by the diagnostic method of present invention comprising administering the patient with a therapeutically effective amount of a CD1d antagonist.

摘要翻译： 本发明涉及用于诊断和治疗CD1d限制性γ/δT细胞淋巴瘤的方法。 特别地，本发明涉及在有需要的患者中诊断作为CD1d限制性γ/δT细胞淋巴瘤的T细胞淋巴瘤的方法，包括：i）检测CD1d受限制的γ/δT淋巴瘤细胞的存在 从患者获得的细胞淋巴瘤样品，以及ii）当在样品中检测到CD1d限制性γ/δT细胞的存在时，认定T细胞淋巴瘤是CD1d限制性γ/δT细胞淋巴瘤。 本发明还涉及通过本发明的诊断方法诊断的用于治疗CD1d限制性γ/δT细胞淋巴瘤的方法，包括给予患者治疗有效量的CD1d拮抗剂。

公开(公告)号：WO2015059072A1

公开(公告)日：2015-04-30

申请号：PCT/EP2014/072398

申请日：2014-10-20

申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  UNIVERSITÉ CLAUDE BERNARD - LYON 1 ,  ENS - ECOLE NORMALE SUPÉRIEURE DE LYON ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)

发明人： LOTTEAU, Vincent ,  ANDRE, Patrice

IPC分类号： A61K31/7068 ,  A61P31/20 ,  A61P13/12 ,  A61P35/00

CPC分类号： A61K31/7068 ,  A61K47/48038 ,  A61K47/48215 ,  A61K47/542 ,  A61K47/60 ,  Y02A50/467 ,  A61K2300/00

摘要： The present invention relates to methods and pharmaceutical compositions for the treatment of polyomavirus infections. In particular, the present invention relates to a method for treating a polyomavirus infection in a subject in need thereof comprising administering the subject with a therapeutically effective amount of gemcitabine.

摘要翻译： 本发明涉及用于治疗多瘤病毒感染的方法和药物组合物。 特别地，本发明涉及治疗有需要的个体的多瘤病毒感染的方法，包括给予受试者治疗有效量的吉西他滨。

公开(公告)号：WO2022167402A1

公开(公告)日：2022-08-11

申请号：PCT/EP2022/052307

申请日：2022-02-01

申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) ,  UNIVERSITÉ CLAUDE BERNARD - LYON 1 ,  ECOLE NORMALE SUPÉRIEURE DE LYON

发明人： VIDALAIN, Pierre-Olivier ,  LOTTEAU, Vincent ,  JANIN, Yves Louis ,  JACQUEMIN, Clémence

IPC分类号： A61K31/437 ,  A61P35/00 ,  A61P37/00 ,  A61K31/196 ,  A61K31/277 ,  A61K31/42 ,  A61K31/444 ,  A61K31/47 ,  A61K31/53 ,  A61K31/4196 ,  A61K31/44 ,  A61K31/4439 ,  A61K45/06

摘要： The nucleosides availability is a crucial factor governing the proliferation of any living entities (viruses, bacteria, parasites or eukaryotic cells). The enzyme involved in the fourth step of the de novo pyrimidine nucleotides biosynthetic pathway, where L-dihydroorotate (DHO) is converted to orotate (ORO), is named dihydroorotate dehydrogenase (DHODH). This enzyme has been recognized as a promising target for the treatment of autoimmune diseases, cancers and infections. However, there is a still a need for identifying new synergic combinations with DHODH inhibitors. The inventors show synergistic effect of DHODH inhibitors and IDH inhibitors on the proliferation of cancer cell lines. The present invention thus relates to methods of therapy comprising administering a therapeutically effective combination comprising a DHODH inhibitor and an IDH inhibitor.

公开(公告)号：WO2022038419A2

公开(公告)日：2022-02-24

申请号：PCT/IB2021/000583

申请日：2021-08-18

申请人： OXFORD INSTRUMENTS ASYLUM RESEARCH, INC. ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) ,  ECOLE NORMALE SUPÉRIEURE DE LYON ,  UNIVERSITÉ CLAUDE BERNARD LYON 1 (UCBL)

发明人： LABUDA, Aleks ,  POTTIER, Basile ,  BELLON, Ludovic

IPC分类号： G01Q20/02 ,  G01B9/02 ,  G01B9/02019 ,  G01B9/02081

摘要： An atomic force microscope ("AFM") based interferometer, uses a light source, and a splitting optical interface, splitting the light beam into a signal light beam and a reference light beam. Both the signal and reference light beams are focused in the vicinity of an AFM cantilever. A beam displacer introduces a lateral displacement between the signal light beam and reference light beam, the lateral displacement being such that, in at least one plane between the beam displacer and the focusing lens structure, the center of the signal light beam is separated from the center of the reference light beam by more than half a sum of their beam diameters on that plane. A detector operates to determine differences in optical path length between the signal light beam and reference light beam to determine information about movement of the cantilever.

公开(公告)号：WO2021204985A1

公开(公告)日：2021-10-14

申请号：PCT/EP2021/059266

申请日：2021-04-09

申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  UNIVERSITÉ D'AIX MARSEILLE ,  ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) ,  ECOLE NORMALE SUPÉRIEURE DE LYON ,  INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT (IRD) ,  UNIVERSITÉ CLAUDE BERNARD - LYON 1

发明人： VIDALAIN, Pierre-Olivier ,  LOTTEAU, Vincent ,  ANDRE, Patrice ,  TOURET, Franck ,  DE LAMBALLERIE, Xavier Nicolas ,  NOUGAIREDE, Antoine

IPC分类号： A61K31/192 ,  A61P31/20

摘要： Coronaviridae is a family of enveloped, positive-sense, single-stranded RNA viruses. The emergence of a new betacoronavirus SARS-CoV-2 has led to a major health-related crisis associated with a significant mortality in intensive care units, due to the pulmonary complications of COVID-19. The inventors showed that Vidofludimus is suitable for inhibiting replication of coronavirus and thus would be suitable for the treatment of infections mediated by said type of virus.

公开(公告)号：WO2019180247A1

公开(公告)日：2019-09-26

申请号：PCT/EP2019/057324

申请日：2019-03-22

申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  ECOLE NORMALE SUPÉRIEURE DE LYON ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS - ,  INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE ,  UNIVERSITE CLAUDE BERNARD LYON 1

发明人： PAIN, Bertrand ,  AURINE, Noémie ,  BAQUERRE, Camille ,  HORVAT, Branka

IPC分类号： C12N5/074

摘要： The disclosure relates to a method for reprogramming somatic cells from mammalian cells including human, bat and equine cells. The inventors have identified an original combination of reprogramming factors for use in methods for reprogramming somatic cells into stem cells from various species, such as bat, bovine, equine and human species. In particular, the disclosure relates to an in vitro method for preparing stem cells reprogrammed from mammalian somatic cells, said method comprising culturing mammalian somatic cells and expressing at least the following combination of reprogramming factors: (i) a reprogramming factor encoded by ESRRB gene, (ii) a reprogramming factor encoded by CDX-2 gene, and, (iii) a reprogramming factor encoded by c-MYC gene, under appropriate conditions for reprogramming said mammalian somatic cells into stem cells.

公开(公告)号：WO2017202789A1

公开(公告)日：2017-11-30

申请号：PCT/EP2017/062308

申请日：2017-05-22

申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  ENS - ECOLE NORMALE SUPÉRIEURE DE LYON ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) ,  UNIVERSITÉ CLAUDE BERNARD LYON 1

发明人： LOTTEAU, Vincent

IPC分类号： A61K31/404 ,  A61K31/4965 ,  A61K31/7068 ,  A61P31/14

摘要： The present invention relates to methods and pharmaceutical compositions for the treatment of filovirus infections. Although several antivirals have shown efficacy against Ebola virus infection in vitro or in animal models, few of them have been yet assessed in human beings with Ebola virus disease. The inventors aimed at identifying novel antivirals showing efficacy against Ebola virus infection. Gemcitabine and obatoclax were identified and their synergistic effects with favipiravir were demonstrated. In particular, the present invention relates to a method of treating a filovirus infection in a subject in need thereof comprising administering to the subject a therapeutically effective combination of favipiravir and Obatoclax. The present invention also relates to a method of treating a filovirus infection in a subject in need thereof comprising administering to the subject a therapeutically effective combination of favipiravir and gemcitabine.

摘要翻译： 本发明涉及用于治疗丝状病毒感染的方法和药物组合物。 虽然有几种抗病毒药物在体外或动物模型中显示出对抗埃博拉病毒感染的功效，但其中很少有人在埃博拉病毒病患者中进行过评估。 本发明人旨在鉴定显示对埃博拉病毒感染有效的新型抗病毒剂。 吉西他滨和obatoclax被确定，并表明它们与favipiravir的协同效应。 具体而言，本发明涉及在有此需要的受试者中治疗丝状病毒感染的方法，其包括向所述受试者施用治疗有效的加利西拉韦和奥巴马克拉唑的组合。 本发明还涉及在有需要的受试者中治疗丝状病毒感染的方法，其包括向受试者施用治疗有效的结合的利福拉韦和吉西他滨。

公开(公告)号：WO2016128349A1

公开(公告)日：2016-08-18

申请号：PCT/EP2016/052614

申请日：2016-02-08

申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  UNIVERSITÉ CLAUDE BERNARD - LYON 1 ,  ENS - ECOLE NORMALE SUPÉRIEURE DE LYON ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)

发明人： REYNARD, Olivier ,  VOLCHKOV, Viktor

IPC分类号： C07K16/10

CPC分类号： C07K16/10 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/76 ,  G01N33/56983 ,  G01N2333/08

摘要： The present invention relates to antibodies or fragments thereof that specifically bind to glycoprotein (GP) of Ebola virus, and to their use for treating and diagnosing Ebola virus disease.

摘要翻译： 本发明涉及特异性结合埃博拉病毒糖蛋白（GP）的抗体或其片段及其用于治疗和诊断埃博拉病毒病的用途。

公开(公告)号：WO2016001698A1

公开(公告)日：2016-01-07

申请号：PCT/IB2014/002163

申请日：2014-06-30

申请人： CENTRE NATIONAL DE LA RECHERCHER SCIENTIFIQUE - CNRS ,  UNIVERSITÉ CLAUDE BERNARD LYON 1 ,  ECOLE NORMALE SUPÉRIEURE DE LYON

发明人： ROSSINI, Aaron ,  ZAGDOUN, Alexandre ,  KUBICKI, Dominik ,  EMSLEY, Lyndon ,  LESAGE, Anne

IPC分类号： G01R33/28 ,  G01R33/62

CPC分类号： G01R33/282 ,  G01R33/62

摘要： The invention provides for a process for polarizing NMR active nuclei within an analyte of interest by dynamic nuclear polarization (DNP), said process comprising the steps of: a. providing a polarizing solution; b. contacting the analyte of interest with the polarizing solution; c. submitting the polarizing solution to DNP conditions, characterized in that it comprises the step of providing a DNP amplifying solid material dispersed or immersed in the polarizing solution, in that the DNP amplifying solid material has a real component of relative permittivity higher than that of the polarizing solution, and in that the volumetric fraction of the DNP amplifying solid material in the final mixture of polarizing solution, analyte and DNP amplifying material is in the range of 10 to 80%, preferably between 15 to 75%, most preferably between 40 to 70 %.

摘要翻译： 本发明提供了通过动态核极化（DNP）在感兴趣的分析物内极化NMR活性核的方法，所述方法包括以下步骤：a。 提供极化解决方案; 湾 使感兴趣的分析物与偏振溶液接触; C。 将偏振溶液提交到DNP条件下，其特征在于包括提供分散或浸没在偏振溶液中的DNP放大固体材料的步骤，因为DNP放大固体材料具有比偏振光更高的相对介电常数的实际分量 溶液，并且在偏振溶液，分析物和DNP扩增材料的最终混合物中的DNP扩增固体材料的体积分数在10至80％的范围内，优选在15至75％之间，最优选在40至70之间 ％。